CAS 2023788-19-2 Tirzepatide

Tirzepatide is a new type of dual receptor agonist of glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory polypeptide), which is administered once a week. Both GLP-1 and GIP are incretins, which are polypeptides secreted by the gastrointestinal mucosa of the human body. The former can bind to receptors on pancreatic islet cells and stimulate insulin secretion, thereby producing a hypoglycemic effect. It can also delay gastric emptying and suppress appetite, thereby controlling weight; while the latter has the functions of inhibiting gastric acid and pepsin secretion, stimulating insulin release, inhibiting gastric motility and emptying, etc., which can complement the effect of GLP-1 receptor agonists. Tirzepatide integrates the effects of two insulinotropic agents into a single molecule, representing a new class of drugs for the treatment of type 2 diabetes.

Company Information

We have cooperated with experienced shipping forwarders for many years, they arrange the shipment. No matter by express, by air or by sea, we will track the course of the goods all the way, to make sure goods arrive at you on time and in good condition.